Drug Approval | September 01, 2022
Zydus receives final approval from USFDA for two tablets
The group now has 322 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04
The group now has 322 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
Bisoprolol Fumarate Tablets are used to treat high blood pressure.
Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
Bringing next-gen cannabinoid therapeutics to cancer patients
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Subscribe To Our Newsletter & Stay Updated
